Dar Al Dawa Development and Investment (AMM:DADI) EPS without NRI: JOD0.16 (TTM As of Mar. 2026)


AMM:DADI Dar Al Dawa Development and Investment AMM:DADI
78 GF Score
Price JOD1.13
GF Value JOD1.10
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Dar Al Dawa Development and Investment EPS without NRI?

Dar Al Dawa Development and Investment AMM:DADI -0.88% 78 EPS without NRI is JOD0.16 as of Mar. 2026. GuruFocus rates AMM:DADI with a GF Score™ of 78/100 and a GF Value™ of JOD1.10 (Fairly Valued). The stock has 4 warning signs investors should review. Among 786 Drug Manufacturers companies, Dar Al Dawa Development and Investment ranks better than 81.81% on this metric.

Dar Al Dawa Development and Investment's earnings per share without non-recurring items for the three months ended in Mar. 2026 was JOD0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was JOD0.16.

During the past 12 months, Dar Al Dawa Development and Investment's average earnings per share (NRI) Growth Rate was 66.70% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 38.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 36.70% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Dar Al Dawa Development and Investment's EPS without NRI or its related term are showing as below:

AMM:DADI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -17.6   Med: 26.9   Max: 56.8
Current: 38.2

During the past 13 years, Dar Al Dawa Development and Investment's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 56.80% per year. The lowest was -17.60% per year. And the median was 26.90% per year.

AMM:DADI's 3-Year EPS without NRI Growth Rate is ranked better than
81.81% of 786 companies
in the Drug Manufacturers industry
Industry Median: 9.6 vs AMM:DADI: 38.20

Dar Al Dawa Development and Investment's EPS (Diluted) for the three months ended in Mar. 2026 was JOD0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was JOD0.15.

Dar Al Dawa Development and Investment's EPS (Basic) for the three months ended in Mar. 2026 was JOD0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was JOD0.17.


Dar Al Dawa Development and Investment  (AMM:DADI) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Dar Al Dawa Development and Investment EPS without NRI Related Terms


Dar Al Dawa Development and Investment EPS without NRI Historical Data

* Premium members only.

The historical data trend for Dar Al Dawa Development and Investment's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dar Al Dawa Development and Investment EPS without NRI Chart

Dar Al Dawa Development and Investment Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.07 0.10 0.10 0.18

Dar Al Dawa Development and Investment Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.03 0.08 0.01

AMM:DADI vs ZTS, UTHR, VTRS: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dar Al Dawa Development and Investment's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dar Al Dawa Development and Investment PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dar Al Dawa Development and Investment's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Dar Al Dawa Development and Investment's PE Ratio without NRI falls into.


AMM:DADI
78GF Score
Dar Al Dawa Development and Investment AMM:DADI
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dar Al Dawa Development and Investment EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was JOD0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of JOD0.16 mean?
Dar Al Dawa Development and Investment (AMM:DADI) has a EPS without NRI of JOD0.16 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Dar Al Dawa Development and Investment and its competitors. According to the industry distribution chart, Dar Al Dawa Development and Investment ranks #143 out of 786 companies in the Drug Manufacturers industry, placing it in the top 18.2%.
Is Dar Al Dawa Development and Investment's EPS without NRI too high?
Dar Al Dawa Development and Investment's current EPS without NRI is JOD0.16. Based on the distribution chart, Dar Al Dawa Development and Investment ranks #143 out of 786 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dar Al Dawa Development and Investment has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dar Al Dawa Development and Investment's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dar Al Dawa Development and Investment ranks #143 out of 786 companies for EPS without NRI. This places Dar Al Dawa Development and Investment in the top 18% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Dar Al Dawa Development and Investment and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dar Al Dawa Development and Investment's current EPS without NRI is JOD0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dar Al Dawa Development and Investment stock overvalued right now?
Based on GuruFocus' analysis, Dar Al Dawa Development and Investment (AMM:DADI) is currently considered Fairly Valued. The stock's GF Value™ is JOD1.10, compared to a current price of JOD1.13 — trading 2.7% above its estimated fair value. The current EPS without NRI is JOD0.16. Dar Al Dawa Development and Investment's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Dar Al Dawa Development and Investment (AMM:DADI), the current EPS without NRI is JOD0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dar Al Dawa Development and Investment (AMM:DADI) Overvalued in 2026?

Based on GuruFocus' analysis, Dar Al Dawa Development and Investment stock appears to be overvalued. The current stock price of JOD1.13 is trading 2.7% above its estimated GF Value™ of JOD1.10. GuruFocus considers Dar Al Dawa Development and Investment to be Fairly Valued.

Key valuation signals for AMM:DADI:

  • EPS without NRI: JOD0.16
  • GF Value™: JOD1.10 vs. price of JOD1.13 (2.7% above fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the AMM:DADI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dar Al Dawa Development and Investment Business Description

Address Naour, P.O. Box 9364, Amman, JOR, 11191
Dar Al Dawa Development and Investment is a pharmaceutical company. The main objectives are the production of medical, chemical, and pharmaceutical products, and importing pharmaceutical products. The subsidiaries' main objectives are marketing and distributing the Company's products, producing some specialized medical products, and investment activities. It offers products in the therapeutic areas of anti-infective, cardiovascular, diabetes, dermatology, eye-ear preparations, gastroenterology and metabolism, genitourinary system and sex hormones, musculoskeletal system, nervous system, ophthalmological/otological, and respiratory system, as well as vitamins. The company's geographical segments are Levant and Iraq, Gulf and Yemen, Africa, and Europe and Asia.
78GF Score

Get the complete analysis for AMM:DADI

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

JOD1.13
Price
JOD1.10
GF Value